Volume 9 Supplement 1

VII Madrid Breast Cancer Conference: Changes in the treatment of breast cancer

Open Access

Frequency of febrile neutropenia in patients treated with taxane/epirubicine and colony-stimulating growth factors for breast cancer: comparison of filgrastim/lenograstim with pegfilgrastim

  • W Schippinger1,
  • R Holub1,
  • N Dandachi1 and
  • T Bauernhofer1
Breast Cancer Research20079(Suppl 1):SP16

https://doi.org/10.1186/bcr1722

Received: 23 May 2007

Published: 19 June 2007

Objective

This report describes a single centre's experience on the efficacy of pegfilgrastim compared with filgrastim or lenograstim in reducing the incidence of febrile neutropenia in patients receiving combination chemotherapy with docetaxel or paclitaxel and epirubicin in neoadjuvant and adjuvant settings.

Methods

A total of 118 patients with breast cancer were treated with either epirubicin 75 mg/m2 and docetaxel 75 mg/m2 or with epirubicin 90 mg/m2 and paclitaxel 200 mg/m2 every 3 weeks; 88 patients received G-CSF support with daily filgrastim or lenograstim and 30 patients with pegfilgrastim once per cycle.

Results

Eight (9.1%) patients with prophylactic filgrastim or lenograstim support developed febrile neutropenia, and one (3.3%) patient in the pegfilgrastim group (P = 0.445). Febrile neutropenia occurred in 13 (2.7%) of 476 filgrastim or lenograstim supported chemotherapy cycles, and in two (1.2%) of 172 cycles with pegfilgrastim support (P = 0.376). The frequency of chemotherapy delays and dose reductions was not significantly different between the two G-CSF treatment groups.

Conclusion

The results of this study demonstrate a trend towards superiority of pegfilgrastim over filgrastim or lenograstim in reducing the frequency of febrile neutropenia in patients treated with taxane and epirubicin chemotherapy regimens for breast cancer.

Authors’ Affiliations

(1)
Hellmut Samonigg Medical University Graz, Department of Internal Medicine, Division of Medical Oncology

Copyright

© BioMed Central Ltd 2007

Advertisement